SNTI - Why Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today? | Benzinga
Senti Biosciences Inc (NASDAQ: SNTI) announced a new strategic collaboration with Celest Therapeutics (Shanghai) Co Ltd, a China-based biotechnology company, for the clinical development of SENTI-301A to treat solid tumors in China.
SENTI-301A is a multi-armed, off-the-shelf, healthy donor-derived CAR-NK cell therapy designed for GPC3-expressing tumors.
Through this collaboration, Celest will lead clinical development, operations, and manufacturing to advance SENTI-301A with technical support from Senti ...